Neurological diseases can significantly reduce the quality and duration of life. Stem cells provide a promising solution, not only due to their regenerative features but also for a variety of other functions, including reducing inflammation and promoting angiogenesis. Although only hematopoietic cells have been approved by the FDA so far, the number of trials continues to expand. We analyzed 492 clinical trials and illustrate the trends in stem cells origins, indications, and phase and status of the clinical trials. The most common neurological disorders treated with stem cells were injuries of brain, spinal cord, and peripheral nerves (14%), stroke (13%), multiple sclerosis (12%), and brain tumors (11%). Mesenchymal stem cells dominated (83%) although the choice of stem cells was highly dependent on the neurological disorder. Of the 492 trials, only two trials have reached phase 4, with most of all other trials being in phases 1 or 2, or transitioning between them (83%). Based on a comparison of the obtained results with similar works and further analysis of the literature, we discuss some of the challenges and future directions of stem cell therapies in the treatment of neurological diseases.
Summary
가장 많이 연구된 질환군은 다음과 같습니다.
가장 많이 사용된 세포
Bone Marrow-derived MSC (BMSC): 30%
Hematopoietic Stem Cells (조혈모세포): 23%
Umbilical Cord MSC (UC-MSC)
Adipose-derived Stem Cells (ADSC)
Neural Stem Cells (NSC)
Mesenchymal stem cell(MSC) 계열이 전체의 83%를 차지하며,그 중 51%는 골수 유래입니다.
DOI : 10.3390/ijms231911453 (논문링크)
Abstract
Neurological diseases can significantly reduce the quality and duration of life. Stem cells provide a promising solution, not only due to their regenerative features but also for a variety of other functions, including reducing inflammation and promoting angiogenesis. Although only hematopoietic cells have been approved by the FDA so far, the number of trials continues to expand. We analyzed 492 clinical trials and illustrate the trends in stem cells origins, indications, and phase and status of the clinical trials. The most common neurological disorders treated with stem cells were injuries of brain, spinal cord, and peripheral nerves (14%), stroke (13%), multiple sclerosis (12%), and brain tumors (11%). Mesenchymal stem cells dominated (83%) although the choice of stem cells was highly dependent on the neurological disorder. Of the 492 trials, only two trials have reached phase 4, with most of all other trials being in phases 1 or 2, or transitioning between them (83%). Based on a comparison of the obtained results with similar works and further analysis of the literature, we discuss some of the challenges and future directions of stem cell therapies in the treatment of neurological diseases.
Summary
가장 많이 연구된 질환군은 다음과 같습니다.
가장 많이 사용된 세포
Bone Marrow-derived MSC (BMSC): 30%
Hematopoietic Stem Cells (조혈모세포): 23%
Umbilical Cord MSC (UC-MSC)
Adipose-derived Stem Cells (ADSC)
Neural Stem Cells (NSC)
Mesenchymal stem cell(MSC) 계열이 전체의 83%를 차지하며,그 중 51%는 골수 유래입니다.
임상 보고 결과로,
부 신경병증에서 신경전도 개선
만성 염증성 탈수초성 신경병증에서 면역억제제 중단 가능 사례
뇌종양에서 고용량 항암요법 후 조혈모세포 이식 병행 시 치료 반응 개선
등이 있으나, 효과는 대부분 '유망하지만 일시적" 라는 평가가 많았습니다.
‘적응증 세분화’로 단순 재생이 아니라
항염증 특화
약물전달 플랫폼화
면역 리셋 전략
등 기전 중심 접근이 중요합니다.